Nathalia Leal Santos

Ms. Nathalia Leal Santos

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Cells
Verified
Journal Article
Open access
PDF file
NSNathalia Leal Santos
Nathalia Leal Santos
SBSilvina Odete Odete Bustos
Silvina Odete Odete Bustos
PRPatricia Reis
Patricia Reis
Roger ChammasRoger Chammas
Roger Chammas
LALuciana Andrade
Luciana Andrade
Management of advanced melanoma remains challenging, with most BRAF (B-Raf proto-oncogene, serine/threonine kinase)-mutated metastatic patients relapsing within a few months upon MAPK inhibitors treatment. Modulation of tumor-derived extracellular vesicle (EVs) cargo with enrichment of antitumoral molecules is a promising strategy to impair tumor progression and increase treatment response. Herein, we report that restored expression of miR-195-5p, down-regulated in melanoma favoring drug resistance, increases the release of EVs enriched in the tumor suppressor miRNAs, miR-195-5p, miR-152-3p, and miR-202-3p. Incorporating these EVs by bystander tumor cells resulted in decreased proliferation and viability, accompanied by a reduction in CCND1 and YAP1 mRNA levels. Upon treatment with MAPK inhibitors, miR-195 EVs significantly decreased BCL2-L1 protein levels and increased cell death ratio and treatment efficacy. Additionally, EVs exogenously loaded with miR-195-5p by electroporation reduced tumor volume in vivo and impaired engraftment and growth of xenografts implanted with melanoma cells exposed to MAPK inhibitors. Our study shows that miR-195-5p antitumoral activity can be spread to bystander cells through EVs, improving melanoma response to targeted therapy and revealing a promising EV-based strategy to increase clinical response in patients harboring BRAF mutations.

4 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SBSilvina Odete Odete Bustos
Silvina Odete Odete Bustos
NSNathalia Leal Santos
Nathalia Leal Santos
Roger ChammasRoger Chammas
Roger Chammas
LALuciana Andrade
Luciana Andrade
Melanoma is the most aggressive skin cancer characterized by high mutational burden and large heterogeneity. Cancer cells are surrounded by a complex environment, critical to tumor establishment and progression. Thus, tumor-associated stromal components can sustain tumor demands or impair cancer cell progression. One way to manage such processes is through the regulation of autophagy, both in stromal and tumor cells. Autophagy is a catabolic mechanism that provides nutrients and energy, and it eliminates damaged organelles by degradation and recycling of cellular elements. Besides this primary function, autophagy plays multiple roles in the tumor microenvironment capable of affecting cell fate. Evidence demonstrates the existence of novel branches in the autophagy system related to cytoplasmic constituent’s secretion. Hence, autophagy-dependent secretion assembles a tangled network of signaling that potentially contributes to metabolism reprogramming, immune regulation, and tumor progression. Here, we summarize the current awareness regarding secretory autophagy and the intersection with exosome biogenesis and release in melanoma and their role in tumor resistance. In addition, we present and discuss data from public databases concerning autophagy and exosome-related genes as important mediators of melanoma behavior. Finally, we will present the main challenges in the field and strategies to translate most of the pre-clinical findings to clinical practice.

1 May 2025 in Clinics
Verified
Journal Article
Open access
RARaphaela Rebeca Silveira Assunção
Raphaela Rebeca Silveira Assunção
NSNathalia Leal Santos
Nathalia Leal Santos
LALuciana Andrade
Luciana Andrade
Cancer is a leading cause of death worldwide, and despite the introduction of new therapeutic approaches for advanced cases aimed at improving patient survival, only a subset of patients benefits from a complete response. In this context, there is a growing need for new cancer biomarkers and therapeutic strategies, and the use of Extracellular Vesicles (EVs) has been widely explored in various approaches. As circulating lipid-bilayer particles carrying a variety of biological information from tumor cells, EVs can be employed as good biomarkers of diagnosis, prognosis, therapy evaluation, and as adjuvants in cancer treatment. In this review, we provide a brief overview of the different types of EVs and their biogenesis and discuss how tumor-derived EV cargo can serve as a potential biomarker in clinical settings through liquid biopsy. We also highlight recent advances in EV nanoengineering and their potential as adjuvants in cancer treatment. Finally, we discuss the key unknowns, gaps, and bottlenecks that must be addressed to fully integrate EVs into precision oncology.

25 October 2026 in Cytotechnology
Verified
Journal Article
Open access
PDF file
NSNathalia Leal Santos
Nathalia Leal Santos
Jean LuzJean Luz
Jean Luz
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
LALuciana Andrade
Luciana Andrade
Three-dimensional (3D) cell culture models, including tumor spheroids and organoids, more accurately recapitulate the structural and physiological complexity of tissues than conventional monolayer cultures, making them valuable platforms for cancer research and drug screening. Volume is a biologically relevant parameter for monitoring growth dynamics and treatment response; however, its quantification often relies on manual image analysis, which is labor-intensive, subjective, and prone to inter-operator variability. Here, we introduce SpheroQuaNNt, a web-based application for automated spheroid segmentation and volume estimation using a U-Net Convolutional Neural Network (CNN). SpheroQuaNNt enables analysis of heterogeneous morphologies through image-based segmentation and provides a web-based interface for volume measurement. The model was trained and validated using 615 microscopy images representing diverse 3D culture systems, including monoculture and hybrid spheroids generated from human and canine tumor cell lines and human embryonic kidney cells, as well as tumor organoids derived from human melanoma lesions. After 30 training epochs, the model achieved 99.35% accuracy during training and 98.56% on the validation dataset, with an average Dice Score of 0.9478 for supervised validation. The method accurately captured volume variations across heterogeneous spheroids, although those presenting marked density heterogeneity between the core and periphery with a dark peripheral margin remained more challenging. Estimated volumes showed strong agreement with measurements performed independently by two experts, supporting its reliability. Overall, SpheroQuaNNt provides a standardized solution for volumetric characterization of spheroids and organoids, reducing operator-dependent variability and supporting high-throughput drug screening and quantitative analysis of 3D cell culture models. Graphical abstract